Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

PFE's non-oncology portfolio draws focus in Q2, with strength in Vyndaqel and Nurtec offsetting some vaccine softness.

With regard to the choice of bone-protecting agent, denosumab (Xgeva) improved bone density and reduced fracture risk in a placebo-controlled trial involving men with non-metastatic HSPC. Denosumab ...

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...

Today’s stock market focus is centered on one single sector: technology stocks. The excitement around artificial intelligence ...

Lee, at this point in the year, all the companies that pay dividends have pretty much set their dividends. You know, the ...

Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line ...

The second healthcare sector IPCEI – approving up to €403 million of State aid by five Member States, including France, ...

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement ...

More than 30 years ago, when Jean-Pascal Tricoire first came to China, his friends gave him the Chinese ...